Clinical Trials

Clinical Research

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. Clinical research includes trials that test new treatments and therapies, genetic studies to explore ways in which a person’s genes may contribute to developing a disorder and epidemiological studies to understand the patterns, causes, and effects of health and disease. 

Clinical Trials

Human clinical trials are a critical phase to bringing safe and effective treatments to market. Many tests are conducted before the clinical trial stage to determine whether potential treatments are appropriate for testing in people. It is through clinical trials that safe and effective drugs, therapies and ultimately, a cure for alopecia areata will be discovered. By participating in a clinical trial, you play an important role in the fight to treat and cure alopecia areata. The decision to participate, however, is very personal and should be made only after speaking with your health care provider and other individuals you trust. You can stop participation in a clinical trial at any time if new concerns arise or you lose confidence that its potential benefits outweigh its risks.

Clinical Trial Resources

ClinicalTrials.gov offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and conditions. Visit ClinicalTrials.gov to review clinical trials that are enrolling around the country on alopecia areata and other diseases.

Clinical Trials and Research Studies

The National Alopecia Areata Foundation is committed to delivering accurate and reliable information to everyone affected by alopecia areata, and subsequently reviews many requests for participation in research studies. The following is a current list of other research studies seeking to recruit people with alopecia areata. 

Disclaimer: NAAF provides research notices as an informational service to its community. NAAF is not conducting the study. This information does not represent a NAAF endorsement, but rather makes you aware that clinical studies are available for your participation if you choose. If you are presently under the care of a physician for alopecia areata, or other conditions, you should discuss this study with your doctor before altering your treatment program. NAAF is not responsible for any adverse outcomes.

Study to Explore Information and Support Needs of Parents with a Child Diagnosed with Alopecia Areata

Last Updated:
09/07/2018
Status:
Completed
Country:
United States
Eligibility:
Parent of child diagnosed with alopecia areata
Sponsor: 
University of Minnesota
A research study at the University of Minnesota is seeking volunteers to learn more about the information and support needs of parents of children with alopecia areata. If you are a parent with one child that has been clinically diagnosed with alopecia areata, your participation in a 15-minute online survey will help us better understand the needs and improve support for parents of children with alopecia areata. Participants will be asked to complete an online survey which includes demographic questions, as well as questions about your experience as a parent. This survey is completely...Read more

Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution in Adult Subjects with Eyebrow Loss due to Alopecia Areata, Alopecia Universalis and Alopecia Totalis

Last Updated:
10/21/2022
Status:
Completed
Country:
United States
Drug:
ATI-50002
Administration:
Topical
Eligibility:
Age 18+; diagnosed with alopecia areata, alopecia universalis or alopecia totalis
Sponsor: 
Aclaris Therapeutics, Inc.
A clinical research study is currently looking for adults with alopecia areata (AA), alopecia universalis (AU), or alopecia totalis (AT) who are experiencing eyebrow hair loss to participate in a study of a topical investigational drug. The purpose of this study is to evaluate the safety, tolerability and effectiveness of a topical investigational drug, ATI-50002, applied to your eyebrow(s) affected with hair loss twice-a-day over 24 weeks. You may qualify to participate if you: Are at least 18 years old Have hair loss on one or both eyebrows due to AA, AU, or AT with a distinct patch of loss...Read more

A Psychological Study of Hair Loss, Self-Compassion and Shame in Adults

Last Updated:
05/09/2018
Status:
Completed
Country:
United Kingdom
Eligibility:
age 18+; diagnosed with alopecia areata, totalis or universalis
Sponsor: 
Plymouth University
Researchers from Plymouth University led by Doctoral Psychologist, Semanthi Sagathevan, are seeking individuals who are living with alopecia areata, universalis, or totalis to participate in a research study. The study is looking that the role of shame and self-compassion in individual experiences of hair loss. Participants are asked to complete an online survey that will take about 10-15 minutes. In order to participate, individuals should be living with, or have lived with alopecia areata, universalis or totalis, and aged 18 years or older. No identifying information will be collected. If...Read more

Improving Quality of Life Outcomes for Individuals Living with Alopecia Areata

Last Updated:
04/25/2018
Status:
Completed
Country:
United States
Eligibility:
age 18+; living with alopecia areata, totalis or universalis
Sponsor: 
Penn State University
A team of researchers from Penn State University led by Dr. Garrett Huck is seeking individuals who are living with alopecia areata, universalis, or totalis to participate in a research study. The goals of this study are to identify strategies that can be useful for assisting individuals living with alopecia areata to live a satisfactory quality of life, despite the presence of their health condition. Participants are asked to complete an online survey that will take approximately 15-30 minutes. In order to participate, individuals should be living with alopecia areata, aged 18 years or older...Read more

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

Last Updated:
04/24/2018
Status:
Completed
Country:
United States
Drug:
ATI-50002
Administration:
Topical
Eligibility:
Age 18+; diagnosed with alopecia universalis or alopecia totalis
Sponsor: 
Aclaris Therapeutics, Inc.
A clinical research study is currently looking for adults with alopecia universalis (total loss of all scalp and body hair including eyebrows, eyelashes, and intranasal hair) or alopecia totalis (total scalp hair loss) to participate in a study of a topical investigational medication. The main purpose of this study is to evaluate the safety and tolerability of a topical investigational medication, ATI-50002, or placebo when applied to your scalp over 4 weeks. During this time, the study will also try to find out how your scalp absorbs, distributes, and gets rid of ATI-50002 or placebo and...Read more

Study on Associations Between Physical Activity, Quality of Life and Mental Health in Alopecia Areata

Last Updated:
08/01/2019
Status:
Completed/Has Results
Country:
Australia
Eligibility:
Age 18+; diagnosed with alopecia areata
Sponsor: 
RMIT University
A research study being conducted at RMIT University is seeking to understand how physical activity impacts your quality of life and mental health. If you are at least 18 years old and living with alopecia areata, your participation in a 25 minute online survey will help increase awareness and the use of physical activity in patients with alopecia areata to improve quality of life and mental health. If you have any questions about the research study, you can contact: Senior supervisor: Dr. Jason Wong at 03 9925 7095 or jason.wong@rmit.edu.au Associate supervisor: Dr. Isaac Selva Raj at 03 9925...Read more

Survey on Coping Styles and Quality of Life in Autoimmune Disease

Last Updated:
03/26/2018
Status:
Completed
Country:
United States
Eligibility:
Age 18+; diagnosed with alopecia areata
Sponsor: 
Midwestern University
A research study being conducted at Midwestern University is seeking to learn more about how coping style mediates depression, anxiety, and quality of life during active and inactive phases of autoimmune disease. The results will inform research on how individuals cope psychologically with disease flare-ups, and if coping style has an impact on disease activity. You must be 18 or older to participate and have been diagnosed with one if the following autoimmune diseases: alopecia areata, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, or type...Read more

Survey Exploring the Sexual Quality of Life in Patients with Alopecia Areata

Last Updated:
03/12/2018
Status:
Completed/Has Results
Eligibility:
Age 18+; diagnosed with alopecia areata
Sponsor: 
Brigham and Women’s Hospital
A research study being conducted by Brigham and Women’s Hospital is seeking to learn more about understanding the sexual quality of life in patients with alopecia areata. If you are a patient who currently has alopecia areata and is at least 18 years old, your participation in a 3-5 minute online survey would be greatly appreciated. Your participation will help improve the care patients receive for their alopecia. Click here for published results.Read more

Study Exploring the Lived Experience of Alopecia Areata

Last Updated:
12/15/2017
Status:
Completed
Country:
United States
Eligibility:
Age 19+; diagnosed with alopecia areata for a period of 6 months or longer
Sponsor: 
The Catholic University of America
Individuals diagnosed with the autoimmune disorder alopecia areata are invited to share their experience by participating in a nursing research study being conducted by Sarah Caro, MS, RN, a Doctoral nursing candidate at The Catholic University of America. The aim of this study is to learn more about the experience of living with alopecia areata from adult men and women 19 years of age and older. The knowledge gained from this research will assist nurses, healthcare providers, and members of the general public and community gain a better understanding of the lived experience of alopecia...Read more

Study To Evaluate The Efficacy And Safety Profile Of Two Investigational Medications For The Treatment of Alopecia Areata

Last Updated:
03/14/2017
Status:
Completed
Drug:
JAK3 inhibitor and TYK2/JAK1 inhibitor
Administration:
Oral
Eligibility:
Age 18-75 with moderate to severe alopecia areata (with fixed hair loss for 7 years or less)
Sponsor: 
Pfizer, Inc.
The purpose of this clinical research study is to evaluate the safety and effectiveness of two investigational medications, in tablet form, or placebo, for the treatment alopecia areata.Read more

Acceptance-based Self-help for Individuals With Visible Difference and Social Anxiety

Last Updated:
08/15/2017
Status:
Completed
Country:
United Kingdom
Eligibility:
Age 18+; living with alopecia areata, totalis or universalis
Sponsor: 
University of Sheffield
Individuals with visible difference commonly experience appearance-related social worry. There are limited resources to help people with appearance-related distress, so internet-provided self-help interventions may be beneficial. An online self-help intervention based upon Acceptance and Commitment Therapy (ACT) has been developed. What is the study about? This study examines whether a self-help booklet based upon ACT is effective in improving social confidence in adults with a visible difference who experience appearance-related social worry. Who is being invited to take part? We are asking...Read more

Survey to Understand the Importance of Eyebrows to those Living with Alopecia Areata

Last Updated:
09/30/2018
Status:
Completed/Has Results
Country:
United States
Eligibility:
Living with alopecia areata, totalis or universalis
Sponsor: 
Yale University School of Medicine
A joint research study between Yale University School of Medicine and Stanford University School of Medicine is recruiting participants for a research project that will study the importance of eyebrows to those with AA. We are interested in learning how eyebrows impact the lives of people with AA and how important they are in the treatment of AA, especially relative to scalp hair. Your participation in this survey will help inform treatment outcomes that matter most to you and raise awareness about all aspects of living with AA including important facial features, such as eyebrows. This...Read more

Study to explore the attitudes and behaviors of people living with alopecia areata

Last Updated:
04/20/2017
Status:
Completed
Country:
United States
Eligibility:
Age 18+; diagnosed with alopecia areata, totalis or universalis
Sponsor: 
Nova Southeastern University
Nova Southeastern University College of Osteopathic Medicine and Public Health is seeking volunteers to participate in a survey on the attitudes and behaviors of people living with alopecia areata toward seeking and accessing psychological counseling; and their satisfaction with the current provider and management. You are eligible to participate if you are 18 years of age or older and have been formally diagnosed with alopecia areata by a physician. Please click here to learn more. For questions, please contact: Angela Kim, DO/MPH Candidate 2017 Nova Southeastern University College of...Read more

Self-help for visible skin difference in adults

Last Updated:
10/21/2022
Status:
Completed
Country:
United Kingdom
Eligibility:
Age 18+; living with alopecia areata, totalis or universalis
Sponsor: 
University of Sheffield
A research study being conducted by researchers from the Department of Psychology at the University of Sheffield is seeking to find out whether a self-help intervention is effective for adults with a visible skin difference. The self-help intervention aims to help people build their confidence in social situations. If your confidence in social situations is affected by your visible skin difference and you are aged 18 or over, you are eligible to participate. Participants in the study will be asked to complete a set of questionnaires. These will be repeated once during the course of the study...Read more

LEO 124249 Ointment in the Treatment of Alopecia Areata

Last Updated:
08/16/2016
Status:
Completed
Country:
United States
Drug:
LEO 124249 Ointment
Administration:
Topical
Eligibility:
Age 18-65; diagnosed with moderate to severe patch type alopecia areata
Sponsor: 
LEO Pharma
The purpose of this study is to investigate the efficacy and safety of LEO 124249 in the treatment of alopecia areata. The following research centers are looking for volunteers to participate in this study that will use an investigational topical product for alopecia areata: Northwestern University Evanston, Illinois Phone: 312-695-3613 The Icahn School of Medicine, Mount Sinai Hospital New York, New York Phone: 212-241-3288Read more

A Study of the Impact of Alopecia Areata on Patients and Families

Last Updated:
07/26/2016
Status:
Completed
Country:
United States
Eligibility:
Living with alopecia areata, totalis or universalis; Parent, spouse, partner, or other family member
Sponsor: 
Yale University School of Medicine
Do you have alopecia areata? Does your child, spouse, partner, or other family member have alopecia areata? A research study being conducted at Yale University School of Medicine is currently recruiting participants for a research project that will study the impact of alopecia areata on quality of life. We are interested in learning about how alopecia areata affects the lives of both the people who live with it, as well as their loved ones. Your participation in this online survey will help raise awareness of the impact of alopecia areata on patients and families. The survey is completely...Read more

A Study with INCB018424 Phosphate Cream Applied Topically to Subjects with Alopecia Areata

Last Updated:
05/05/2016
Status:
Completed
Country:
United States
Drug:
INCB018424 Phosphate Cream
Administration:
Topical
Eligibility:
Age 18-70; diagnosed with patch type alopecia areata
Sponsor: 
Incyte Corporation
The purpose of this study is to find out if the drug INCB018424 Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.Read more

A Study to Identify Autoimmune Epitopes in Alopecia Areata

Last Updated:
05/05/2016
Status:
Completed
Country:
United States
Eligibility:
Age 18+; diagnosed with alopecia areata, totalis or universalis
Sponsor: 
La Jolla Instistute for Allergy and Immunology
La Jolla Instistute for Allergy and Immunology is seeking volunteers to provide a standard blood donation for a study to better understand the immune response in alopecia areata. The purpose of this study is to identify and thoroughly characterize autoimmune epitopes present in alopecia areata. Understanding the pathophysiology of alopecia areata is essential for the development of future treatments and may help lead to better therapies for immune related hair loss in the future.Read more

A Study of the Lived Experience of Alopecia Areata Women

Last Updated:
07/22/2016
Status:
Completed
Country:
United States
Eligibility:
Women ages 30-35; diagnosed with alopecia areata, universalis or totalis in early adulthood
Sponsor: 
University of Minnesota
A research study being conducted at the University of Minnesota is seeking to better understand the experiences of women ages 30-35 who currently have alopecia areata (including universalis, or totalis), and developed their alopecia areata while in high school. By taking a small amount of your time to participate in this study you are helping uncover the story of what it is like to have alopecia areata. A $20 gift card will be provided to all participants as compensation for their time. Participants in the study are asked to take part in two interviews with the researcher. The interview can...Read more

A Study of Secukinumab for the Treatment of Alopecia Areata

Last Updated:
05/05/2016
Status:
Completed
Country:
United States
Drug:
Secukinumab
Administration:
Injection
Eligibility:
Age 18+; patch type alopecia areata
Sponsor: 
Icahn School of Medicine at Mount Sinai
Ichan School of Medicine at Mount Sinai is seeking volunteers for a study evaluating the effectiveness of a new study drug in the treatment of moderate to severe alopecia areata. The purpose of this study is t o assess the effects of a new treatment called secukinumab in patients with alopecia areata .Read more

Intralesional Steroids in the Treatment of Alopecia Areata

Last Updated:
05/05/2016
Status:
Completed
Country:
United States
Drug:
Intralesional Triamcinolone
Administration:
Injection
Eligibility:
Age 18-75; patch type alopecia areata
Sponsor: 
Columbia University
Intralesional steroids are the most commonly used treatment for alopecia areata, yet much remains unknown about the risks and benefits of different doses of intralesional steroids. The goal of this study is to answer some of those questions.Read more

Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata

Last Updated:
05/05/2016
Status:
Completed
Country:
United States
Drug:
Abatacept
Administration:
Injection
Eligibility:
Age 18-75; patch type alopecia areata
Sponsor: 
Columbia University
Many people in the U.S. suffer from alopecia areata, yet treatment options are limited and sometimes painful. The goal of this study is to test a medication, given as a subcutaneous injection that acts on the immune system and may reverse hair loss.Read more

Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata

Last Updated:
05/09/2016
Status:
Completed
Country:
United States
Drug:
Ruxolitinib
Administration:
Oral
Eligibility:
Age 18-75; patch type alopecia areata
Sponsor: 
Columbia University
Many people in the U.S. suffer from alopecia areata, yet treatment options are limited and sometimes painful. The goal of this study is to test a new medication taken as a pill that acts on the immune system and may reverse hair loss.Read more

The Family System and Alopecia Areata: A Phenomenological Study of Family Members' Lived Experiences

Last Updated:
05/05/2016
Status:
Completed
Country:
United States
Eligibility:
Age 18+; family member diagnosed with alopecia areata, totalis or universalis
A doctoral student is conducting voluntary confidential interviews to explore the experiences of family members of persons diagnosed with alopecia areata. The desired results of this study will aid family therapists and other professionals to better help those living with alopecia areata, as well as their families.Read more

Type 1 Diabetes TrialNet

Last Updated:
10/21/2022
Status:
Recruiting
Country:
United States
Eligibility:
Age 1-45 with 1st degree relative with T1D; Age 1-20 with 2nd/3rd degree relative with T1D
Sponsor: 
National Institute of Diabetes and Digestive and Kidney Diseases
Type 1 Diabetes TrialNet (TrialNet) is an international network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes. Alopecia Areata families have a higher incidence of other autoimmune diseases, including type 1 diabetes (T1D). Relatives of someone with T1D have 15 to 20 times the risk to develop the disease. TrialNet is offering T1D risk screening to blood relatives of someone with T1D through a blood test performed at no cost and available anywhere in the US.Read more

Pages